TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06373380
Drug: HB-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every (21 days) intravenously for 4 doses (2 doses each of HB-202 and HB-201 alternating).
Study: NCT05993078
Drug: 0.9% NaCl 2000ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will undergo NS 2000ml intravenous infusion immediately after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
Study: NCT05993078
Drug: 0.9% NaCl 200-400ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients receive an NS 200-400ml after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
Study: NCT05252754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO, 1-2 hours prior to endoscopy.
Study: NCT05252754
Drug: Rectal Indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
Study: NCT05838131
Drug: Experimental: CAR-T cells Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological:~chimeric antigen receptor T cells
Study: NCT06592417
Drug: JSKN016 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.
Study: NCT06612944
Drug: Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 AZA + BCL2 Inhibitor (Preferred Regimen) Subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; BCL2 inhibitor (VEN): 400 mg per day orally for one week (if combined with a CYP450 inhibitor, reduce to 100 mg per day).~1.2 AZA (DEC) + DLI For patients with TP53 mutations or those who do not respond to VEN, subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; decitabine at 5 mg/m² per day for 5 consecutive days, with a 28-day cycle (preferred for those with TP53 mutations). For patients without the option for DLI, regimen 1.1 is recommended.~DLI: Begins 3 months post-transplantation, starting with a dose of 1×10\^5 CD3+ T lymphocytes for haploidentical transplants, with doses increasing every 4-6 weeks to 5×10\^5 CD3+ T lymphocytes, 1×10\^6 CD3+, and 5×10\^6 CD3+ T lymphocytes; for full-matched transplants, the starting dose is 5×10\^5 CD3+ T lymphocytes with dose escalations as above to 1×1
Study: NCT05726396
Drug: RMT
Normalized name: Dermtex HC
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single loading dose of RMT capsules containing \~5 x 10 11 bacteria on day 1 followed by 2 x 10 11 bacteria daily for 6 days. The RMT capsule preparation (\~2-5 capsules, size 00) is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
Study: NCT05726396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an identical looking placebo capsules daily for 7 days (i.e 5 placebo capsules on day 1), followed by 2 placebo capsules daily from Day 2-7. The placebo capsule preparation is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
Study: NCT05728229
Drug: Supplement with SiderAl® Med
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation with special purpose food
Study: NCT05029882
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05743036
Drug: ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c3 tablet by mouth, in combination with encorafenib
Study: NCT05813106
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT05019326
Drug: Andrographis Paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
Study: NCT05019326
Drug: Boesenbergia
Normalized name: BOESENBERGIA ROTUNDA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
Study: NCT04968002
Drug: pablizumab combined with apatinib and neoadjuvant chemotherapy
Normalized name: picodralazine and diuretics, combinations with psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients with stage IIa-IIIa non-small cell lung cancer are treated with pablizumab combined with apatinib and neoadjuvant chemotherapy
Study: NCT05400317
Drug: AD-218A
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 12weeks
Study: NCT06155903
Drug: Anesthesiological mixtures (Spinal anesthesia)
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg.
Study: NCT06155903
Drug: Anesthesiological mixtures (Peripheral nerve block)
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
Study: NCT06783647
Drug: LBL-024 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W; intravenous infusion;Each infusion is usually completed within 30-120 minutes
Study: NCT05854667
Drug: Treatment as Usual plus Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
Study: NCT05854667
Drug: Treatment as Usual plus Placebo plus Contingency Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
Study: NCT06191991
Drug: ALG-055009
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg
Study: NCT06191991
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg
Study: NCT04140721
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill identical to moxonidine administered for 4 weeks
Study: NCT05249556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for ganaxolone)
Study: NCT06493578
Drug: VYN201 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: VYN201 Gel is a topical formulation applied as a thin layer to affected areas.
Study: NCT06493578
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel (placebo) is matching in appearance to VYN201 gel and is to be applied in the same manner as VYN201 gel.
Study: NCT05869669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a capsule that looks just like neflamapimod but without the active ingredients
Study: NCT05844462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT05524051
Drug: TIN816
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIN816
Study: NCT05951777
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Saline Solution 0.9%
Study: NCT04941989
Drug: HTL0022562
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0022562
Study: NCT04941989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05994742
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin is a macrolide antibiotic, and is approved for use in children by the FDA (ID: 3263750) and EMA (EMA/2872/2021).
Study: NCT05994742
Drug: Pyridoxine Hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine is a form of vitamin B6 used to prevent peripheral neuropathy among children receiving isoniazid.
Study: NCT05865470
Drug: Smoked Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Cannabis
Study: NCT05865470
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT05882760
Drug: Tetric N Bond Universal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch \& Rinse Tetric - N - Bond (Ivoclar)
Study: NCT05882760
Drug: Self Etch Tetric N Bond Universal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®
Study: NCT05882760
Drug: GC Fuji IX, GC, Japan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavities will be restored with GC Fuji IX, GC, Japan®
Study: NCT05882760
Drug: Activa TM Bioactive Restorative ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavities will be restored with Activa TM Bioactive Restorative ®
Study: NCT04975516
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given chemotherapy
Study: NCT05728658
Drug: ICP-248
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
Study: NCT04667663
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
Study: NCT06101745
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Phase 3A only, 50 subjects will be randomly allocated to receive sugar placebo
Study: NCT04969835
Drug: AVA6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVA6000 is a FAP-activated doxorubicin.
Study: NCT05751967
Drug: Placebo Combined With Ursodeoxycholic Acid
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet/ day
Study: NCT05751967
Drug: Fenofibrate Combined With Ursodeoxycholic Acid
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day
Study: NCT05853601
Drug: Single Dose Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are given a single loading dose of theophylline, 5mg/kg IV, within 18 hours after birth. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
Study: NCT05853601
Drug: Repeat Dose Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are given a loading dose of theophylline, 5mg/kg IV, within 18 hours of birth, and then two subsequent doses (1.2mg/kg iv) at 12 hours and 24 hours after loading dose. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
Study: NCT05813496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.
Study: NCT06377566
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 25 mg/m\^2 IV
Study: NCT05731128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection solution subcutaneous
Study: NCT05017571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 capsule per day
Study: NCT05918861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets
Study: NCT05904236
Drug: Treatment with ICVB-1042 administered intravenously
Normalized name: IV SOLUTIONS WITH ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
Study: NCT05639543
Drug: INT-787
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded Study Drug
Study: NCT05639543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05555888
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study: NCT05863234
Drug: PPMX-T003
Approvals — FDA: no, EMA: no, PMDA: no
Description: The therapeutic agent is administered continuously intravenously
Study: NCT04495452
Drug: Fentanyl Drug Administration
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
Study: NCT06135974
Drug: LC106
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus
Study: NCT06135974
Drug: LC115
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 15 strains of Lactobacillus crispatus
Study: NCT06135974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal tablets containing primarily microcrystalline cellulose and no live bacteria
Study: NCT06191263
Drug: RVU120
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Study: NCT05840809
Drug: First line tuberculosis treatment
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study - the decision to use first-line tuberculosis treatment will have already been made by the responsible clinician. The study itself does not require any additional intervention.
Study: NCT06324396
Drug: Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of pravastatin will be administered to all study subjects.
Study: NCT06367283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
Study: NCT04747912
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
Study: NCT06473740
Drug: Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen)
Normalized name: deoxyribonucleases / plasmin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug Neovasculgen is a highly purified supercoiled form of the pCMV-VEGF165 plasmid, encoding the Vascular endothelial growth factor (VEGF) under the control of a promoter (DNA control region). Recombinant plasmid DNA consists of the following components: a fragment of the regulatory region (22 nucleotide pairs), which determines the transcription of the gene, the VEGF minigene, upon expression of which the VEGF isoform is synthesized, consisting of 165 amino acids, a splicing signal, a polyadenylation signal and the SV40 transcription terminator, ensuring the synthesis of the mature RNA gene and auxiliary regions required for efficient biosynthesis of plasmid DNA in the cells of the producer strain of Escherichia coli. When molecules of this plasmid penetrate into mammalian cells, VEGF is produced, which stimulates endothelial cells, which leads to the growth of blood vessels (vascularization) in the area of injection.
Study: NCT04738123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsules
Study: NCT05731726
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05731726
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celebrex
Study: NCT05799820
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
Study: NCT00000912
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05870358
Drug: Melatonin 3 MG
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
Study: NCT05978063
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo administered twice daily
Study: NCT06332274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form : Solvent IV bags used for dilution of tislelizumab (for example: CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable) Dose Regimen: every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV.
Study: NCT05737069
Drug: Ibuprofen arginine granules 400 mg
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
Study: NCT05737069
Drug: Ibuprofen arginine granules 400 mg (Spedifen)
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
Study: NCT06135805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of placebo oral gel on oral lesions
Study: NCT06305793
Drug: IVIG (intravenous immunoglobulin)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IVIG for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).
Study: NCT06305793
Drug: IVIG Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo.~Participants will receive placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).
Study: NCT05961839
Drug: SGR-2921
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGR-2921 will be administered orally.
Study: NCT05750264
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg of IV ibuprofen
Study: NCT06285396
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine, at applicable concentrations based on literature.
Study: NCT05978193
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years
Study: NCT05978193
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles
Study: NCT06273774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06654011
Drug: IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, orally, once daily
Study: NCT06596512
Drug: PARTICS using a single ICS add on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to PARTICS who use a nebulizer less than once a week are instructed to use the study prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.
Study: NCT06595186
Drug: JK-1201I
Approvals — FDA: no, EMA: no, PMDA: no
Description: JK-1201I will be administered.
Study: NCT04912869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
Study: NCT06594224
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.
Study: NCT05548582
Drug: Acetaminophen 500 mg Tab
Normalized name: Acetaminophen 500 mg tablet for oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prescription
Study: NCT05548582
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard prescription
Study: NCT06412471
Drug: SSGJ-707
Approvals — FDA: no, EMA: no, PMDA: no
Description: bispecific antibody